Linda Mileshkin et al., 2005-06: Published criticism of Morgan et al. arguing the 2.3%/2.1% figures are artefacts of the denominator and the 5-year cut-off. The authors also allege specific errors: omission of leukaemias and Burkitt's lymphoma, understated ovarian and head-and-neck effects (8% not 4%), and no account of palliative benefit.
By using all newly diagnosed adult patients as a denominator, despite the fact that chemotherapy is not indicated for many of these patients, the magnitude of the benefit in many sub-groups is obscured.
Letter text (journal p. 294)
Linda Mileshkin et al., 2005-06: Published criticism of Morgan et al. arguing the 2.3%/2.1% figures are artefacts of the denominator and the 5-year cut-off. The authors also allege specific errors: omission of leukaemias and Burkitt's lymphoma, understated ovarian and head-and-neck effects (8% not 4%), and no account of palliative benefit. This is the main published objection to C2 as stated: the critics say the percentage is computed over all incident cases rather than over patients for whom chemotherapy is indicated. Full letter text is on the PubMed record and was read there. Funder/COI: not stated in the letter. No reply from Morgan et al. was located in this run. Note the letter's own claim that 10-year absolute gain in breast cancer is 7% (node-negative) and 11% (node-positive) under 50 – i.e. the critics accept small absolute gains. Study type: other.
